Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor

Published:2018-03-25 Issue:4 Volume:109 Page:1207-1219
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Xie Chengying¹,Wan Xiaozhe¹,Quan Haitian¹,Zheng Mingyue¹,Fu Li¹,Li Yun¹,Lou Liguang¹^ORCID

Affiliation:

1. Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai China

Funder

National Natural Science Foundation of China

Science and Technology Commission of Shanghai Municipality

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.13536

Reference59 articles.

1. Molecular mechanisms of blood vessel formation

2. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications

3. Angiogenesis in health and disease

4. Clinical Applications of Research on Angiogenesis

5. Angiogenesis

Cited by 247 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case report: outcome of anlotinib treatment in breast cancer patient with brain metastases;Frontiers in Pharmacology;2024-08-19

2. Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial;Signal Transduction and Targeted Therapy;2024-08-13

3. Design and Synthesis of New Dihydropyrimidine Derivatives with a Cytotoxic Effect as Dual EGFR/VEGFR-2 Inhibitors;ACS Omega;2024-08-01

4. Anlotinib destabilizes PAX3-FOXO1 to induce rhabdomyosarcoma cell death via upregulating NEK2;Biomedicine & Pharmacotherapy;2024-08

5. Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment;2024-06-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3